Take­da R&D team rings the block­buster bell with key PhI­II suc­cess in front­line lung can­cer

Take­da R&D chief Andy Plump hit the mon­ey shot with a head-to-head Phase III study pit­ting Alun­brig (briga­tinib) against Pfiz­er’s Xalko­ri in a group of ALK+ non-small cell lung can­cer pa­tients.

Re­searchers say their drug hit the pri­ma­ry end­point on pro­gres­sion-free sur­vival. Cur­rent­ly not ap­proved for front­line use, the drug was test­ed in pa­tients who had not yet re­ceived an ALK in­hibitor.

Ap­proved last April for treat­ment-re­sis­tant cas­es of ALK+ NSCLC, Take­da has been pur­su­ing ev­i­dence that their drug can gar­ner more than a bil­lion dol­lars a year in sales, a stretch above the $500 mil­lion to $800 mil­lion mark that an­a­lysts have pro­ject­ed. And now they plan to hus­tle up a sup­ple­men­tal ap­proval to help make that fore­cast a re­al­i­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.